0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA's Gottlieb Suggests

  • PDF Icon

    Newsletter

  • 3 Pages
  • December 2024
  • Region: Global
  • Citeline
  • ID: 4775330
US FDA Commissioner Scott Gottlieb said at a recent policy conference that chimeric antigen receptor T-cell (CAR-T) therapies may soon be relabeled for outpatient use, easing the cost of these new therapies for providers, while furnishing coverage under the Medicare Part B plan.

Find out more about the financial concerns for CAR-T therapies, the impact that outpatient CAR-T therapies would have on Medicare c. and what it means for both providers and for Medicare, in this essential article from Pink Sheet.
This website uses cookies to ensure you get the best experience. Learn more